Vivo Capital’s Monopar Therapeutics MNPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.21M Hold
90,500
– – 0.79% 33
2026
Q2
$8.38M Hold
90,500
– – 0.77% 33
2026
Q1
$4.96M Hold
90,500
– – 0.41% 36
2025
Q4
$5.91M Hold
90,500
– – 0.38% 38
2025
Q3
$7.39M Buy
+90,500
New +$4.05M 0.59% 37

Other funds holding MNPR

Vivo Capital's MNPR Position: Q3 2026 in Review

Vivo Capital held its Monopar Therapeutics (MNPR) position steady in Q3 2026 at 90,500 shares worth $7.21M. The position accounts for 0.79% of the portfolio, ranked #33.

Vivo Capital first reported a position in MNPR in Q3 2025 and has held it in 5 quarters since. The position peaked at $8.38M in Q2 2026. 104 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • Vivo Capital held 90,500 shares of Monopar Therapeutics worth $7.21M as of Q3 2026.
  • Vivo Capital left its Monopar Therapeutics share count unchanged in Q3 2026.
  • Monopar Therapeutics made up 0.79% of Vivo Capital's portfolio in Q3 2026, its #33 holding.
  • Vivo Capital first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Vivo Capital's Monopar Therapeutics position peaked at $8.38M in Q2 2026.
  • 104 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.